5 HaEshel Street

P.O.Box 3036
Caesarea Industrial Park
Caesarea, Israel 3079815
Tel. +972 4 9948883

© 2020 by PTM-Biosciences

ABOUT

COMPANY

PTM Biosciences is pioneering
proteomics-based personalized medicine

PTM Biosciences is employing innovative and state-of-the art proteomic-based solutions
conceived by Yifat Merbl, PhD, generating proprietary, novel data for biomarker discovery & therapeutics

TEAM

A multidisciplinary diversified team 

Baruch Schori, Msc, MBA

CEO

Baruch is a seasoned executive in healthcare and technology ventures with broad, diversified experience as an entrepreneur, as a business and technology leader, and as a venture capitalist. Baruch was as a technical manager at the Aircraft Simulators division at Elbit Systems, international developer of defense and homeland security solutions. He later was responsible for marketing and business development at Omniguide, a US-based medtech startup, developing minimally invasive laser-based surgical tools. In 2006, Baruch joined Medica Venture Partners investment team, managing Medica3 fund - a $115 million healthcare focused fund investing in medtech and biotech companies. Recently, Baruch led the bidding and setup processes of three Israel Innovation Authority (IIA) healthcare incubators, each owned by a multinational consortium, composed of pharma/medtech leaders.
Baruch holds a BSc in Information Systems Engineering, cum laude, from the Technion, an MSc in Health Science and Technology from Harvard-MIT Division of Health Science and Technology, and an MBA from the Sloan School of Management at MIT.

Yifat Merbl, PhD

Co-founder and CTO

Dr. Merbl joined the immunology Department at the Weizmann Institute of Science in 2014 as the incumbent of the Leonard and Carol Berall Career Development Chair. The Merbl lab focuses on elucidating molecular mechanisms of protein modifications in Cancer and Immune regulation with more than 15 research fellows at all training levels, working on various biological topics. The work at the Merbl lab involves diverse disciplines ranging from biochemistry, proteomics to cancer research and in vivo work. Dr. Merbl has recently received the Starting grant award by the ERC as well as the Gruber award for young investigators and the Alon Fellowship for excellence in Science.
Dr. Merbl holds a BSc in Computational Biology, summa cum laude, from the Bar Ilan University, and an MSc in Immunology from the Weizmann Institute of science. Dr. Merbl performed her post doctorate and doctorate work in Systems Biology at the Harvard Medical School, where she focused on fundamental processes in cell division and regulation of post-translational modifications.

Shimon Alon 

Chairman of the Board and Investor

Mr. Alon serves as the CEO and Chairman of the Board of Attunity Ltd (ATTU.A), a provider of Big Data management software solutions that enable access, management, sharing and distribution of data across heterogeneous enterprise platforms, organizations and the cloud. Previously Mr. Alon was CEO of Precise Software Solutions, a leading provider of application performance management. Following the acquisition of Precise by VERITAS Software Corporation in June 2003, Mr. Alon served as an executive advisor to VERITAS. Prior to Precise Software, Mr. Alon held a number of positions at Scitex and its subsidiaries including President and CEO of Scitex America and Managing Director of Scitex Europe. Mr. Alon holds a degree from the Executive Management Program at the Harvard Business School.

Prof. Aaron Ciechanover, MD, DSc

Scientific Advisory Board

Prof. Ciechanover, a distinguished research Professor in the Faculty of medicine at the Technion, Israel Institute of Technology. Prof. Ciechanover received his M.Sc. and M.D. from the Hebrew University in Jerusalem, and his D.Sc from the Faculty of Medicine in the Technion. There, as a graduate student with Dr. Avram Hershko and in collaboration with Dr. Irwin A. Rose from the Fox Chase Cancer Center in Philadelphia, USA, they discovered that covalent attachment of ubiquitin to a target protein signals it for degradation. They deciphered the mechanism of conjugation, described the general proteolytic functions of the system, and proposed a model according to which this modification serves as a recognition signal for a specific downstream protease. As a post- doctoral fellow with Dr. Harvey Lodish at the M.I.T., he continued his studies on the ubiquitin system and made additional important discoveries.
Along the years, it has become clear that ubiquitin-mediated proteolysis plays major roles in numerous cellular processes, and aberrations in the system underlie the pathogenetic mechanisms of many diseases, among them certain malignancies and neurodegenerative disorders. Consequently, the system has become an important platform for drug development.
Among the numerous prizes Ciechanover received are the 2000 Albert Lasker Award, the 2003 Israel Prize, and the 2004 Nobel Prize (Chemistry; shared with Drs. Hershko and Rose).
Prof. Ciechanover is a member of the Israeli National Academy of Sciences and Humanities, The European Molecular Biology Organization, the American Academy of Arts and Sciences, the American Philosophical Society, the National Academies of Sciences and Medicine of the USA, the Pontifical Academy of Sciences at the Vatican, the Chinese Academy of Sciences, the Russian Academy of Sciences, and the German Academy of Sciences.

 
ptm-logo-white-trns.png